PRESS RELEASES
Edoxaban Significantly Reduces Risk of Venous Thromboembolism by Half Compared to Enoxaparin in Japanese and Taiwanese Patients Following Knee or Hip Arthroplasty Surgery
MUNICH, December 14, 2011 /PRNewswire/ --
Pooled results of the STARS E-III and STARS J-V studies presented at the 2011 American Society of Hematology (ASH) Annual Meeting
Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) today announced the results of a pooled analysis showing that edoxaban*, a direct oral once-daily factor Xa inhibitor, significantly reduced the risk of developing venous thromboembolism (VTE) following total knee or hip arthroplasty when compared to enoxaparin.[1] Patients receiving edoxaban had a lower incidence of a composite of deep vein thrombosis (DVT) and pulmonary embolism (PE) than those treated with enoxaparin (5.1% vs. 10.7%, P<0.001, Relative Risk Reduction [RRR] 52.7%, Absolute Risk Reduction [ARR] -5.6%), an effect that was shown without a statistically significant difference in bleeding between the groups.[1]
The analysis drew data from two randomised, double-blind, double-dummy, phase III studies (STARS E-III and STARS J-V) of 1,326 Japanese and Taiwanese patients[1] who had underwent total knee arthroplasty (TKA) or total hip arthroplasty (THA).[2,3] Results were presented in an oral session at the 53rd Annual Meeting of the American Society of Hematology in San Diego, USA.[1]
"Total hip and knee arthroplasty surgeries place patients at a higher risk of DVT, which can lead to thromboembolic disease such as PE," said Dr. Takeshi Fuji, Head of Orthopaedic Surgery, Osaka Koseinenkin Hospital, Osaka Japan. "As the number of these surgeries increases and the incidence of VTE is expected to double by the year 2050,[4] it will become increasingly important for physicians to have a number of treatment options to prevent DVT and PE following these surgeries."
The incidence of major and Clinically Relevant Non-Major (CRNM) bleeding events in the edoxaban* and enoxaparin groups was 4.6% vs. 3.7%, respectively (P=0.427).[1] A further subgroup analysis of major and CRNM bleeding indicated no significant difference between edoxaban and enoxaparin in any of the patient subgroups evaluated, based on age, weight, or creatinine clearance.[1]
Patients enrolled in the STARS E-III (Japanese and Taiwanese patients) and STARS J-V (Japanese patients) studies were randomised to receive either oral edoxaban 30 mg once daily or subcutaneous enoxaparin 20 mg (2,000 IU) twice daily for 11-14 days,[2,3] in line with standard clinical practice in Japan.
"We are pleased to see positive outcomes with edoxaban in this patient population," said Dr. Kazunori Hirokawa, Global, Head of R&D Unit, Daiichi Sankyo Co., Ltd. "These results further support the safety and efficacy of edoxaban in the prevention of DVT and PE following major orthopaedic surgery. Daiichi Sankyo remains committed to developing edoxaban in our global clinical trials program."
About Edoxaban
Edoxaban is a once-daily oral anticoagulant that directly inhibits Factor Xa, an important factor in the coagulation process.[5] Edoxaban is currently available only in Japan, licensed for the prevention of venous thromboembolism (VTE) in patients undergoing total knee arthroplasty, total hip arthroplasty and hip fracture surgery.[6] Daiichi Sankyo continues to develop edoxaban at a global level as a potential new treatment for stroke prevention in atrial fibrillation, and the treatment and prevention of recurrent VTE. Notably, Daiichi Sankyo has more than 25 years experience conducting research in the area of Factor Xa inhibition and was the first company to study these compounds in humans.
About the Pooled STARS Analysis
The analysis drew data from two Phase III comparative studies, STARS E-III and STARS J-V.[2,3]
Both studies supported the March 2010 edoxaban New Drug Application (NDA) in Japan seeking approval for the prevention of VTE after major orthopaedic surgery. In the studies, edoxaban was initiated six to 24 hours after surgery; enoxaparin was initiated 24 to 36 hours after surgery,[2] the standard of care in Japan. The primary efficacy outcome in both studies was the composite of symptomatic and asymptomatic DVT and PE.[2,3] The principal safety outcome was incidence of major and clinically relevant non-major bleeding.[2,3]
About Venous Thromboembolism
VTE is the term for the generation of a blood clot within a vein, or the subsequent breaking off of that clot into a pulmonary (lung) artery.[7,8] Deep vein thrombosis (DVT) and pulmonary embolism (PE) are the two sub-types of VTE.[7] DVT is a blood clot anywhere in the deep veins of the legs, pelvis or arms.[9] PE is a clot that detaches from the vein and travels to the lungs,[9] lodging in the pulmonary arteries causing a potentially fatal condition.[9,10] PE is often accompanied by DVT and a DVT can develop into a PE suddenly.[10]
Patients with diagnosed VTE are treated for three to six months (and sometimes even longer) based on their individual risk profile to prevent a second (recurrent) DVT or PE.[10] VTE is the cause of significant mortality; 30% of people with VTE die within one month of diagnosis and about 25% of those with PE experience sudden death.[11] Additionally, about 30% of those affected will experience a recurrence of DVT/PE within 10 years of the initial DVT/PE diagnosis.[11]
About Daiichi Sankyo
The Daiichi Sankyo Group is dedicated to the creation and supply of innovative pharmaceutical products to address the diversified, unmet medical needs of patients in both mature and emerging markets. While maintaining its portfolio of marketed pharmaceuticals for hypertension, hyperlipidemia, and bacterial infections, the Group is engaged in the development of treatments for thrombotic disorders and focused on the discovery of novel oncology and cardiovascular-metabolic therapies. Furthermore, the Daiichi Sankyo Group has created a "Hybrid Business Model," which will respond to market and customer diversity and optimise growth opportunities across the value chain.
The company's world headquarters are in Tokyo. Its European base is located in Munich. Daiichi Sankyo Europe has affiliates in 12 European countries in addition to a global manufacturing site located in Pfaffenhofen, Germany.
For more information, please visit: http://www.daiichisankyo.com/ or http://www.daiichi-sankyo.eu/
Forward-looking statements
This press release contains forward-looking statements and information about future developments in the sector, and the legal and business conditions of Daiichi Sankyo Europe GmbH. Such forward-looking statements are uncertain and are subject at all times to the risks of change, particularly to the usual risks faced by a global pharmaceutical company, including the impact of the prices for products and raw materials, medication safety, changes in exchange rates, government regulations, employee relations, taxes, political instability and terrorism as well as the results of independent demands and governmental inquiries that affect the affairs of the company. All forward-looking statements contained in this release hold true as of the date of publication. They do not represent any guarantee of future performance. Actual events and developments could differ materially from the forward-looking statements that are explicitly expressed or implied in these statements. Daiichi Sankyo Europe GmbH assumes no responsibility for the updating of such forward-looking statements about future developments of the sector, legal and business conditions and the company.
*. Edoxaban is licensed only in Japan for the prevention of VTE after major orthopaedic surgery, under the brand name Lixiana® In Europe, edoxaban has not been approved yet. Daiichi Sankyo continues to develop edoxaban at a global level as a potential new treatment for stroke prevention in atrial fibrillation, and the treatment and prevention of recurrent VTE.
References
IAF's MiG-29 crashes near Agra in Uttar Pradesh, pilot ejects safely, court of inquiry ordered
Driving Growth and Monetization at Zendesk: A Conversation with Darshit Thakkar
Can air pollution make you fat? Know how high AQI impact your health
Locanto Addresses Challenges and Innovations in Indian Education System
Nita Ambani stuns in floral co-ord set while Anant, Mukesh Ambani go casual in Dubai
Indian Railway to launch this 'SUPER APP', passengers can now..., know details here
Who is Rashmi Shukla, IPS officer whom EC removed as Maharashtra DGP?
This village in India allows men to have two wives, living under one roof due to…
AUS vs PAK, 1st ODI: Australia beat Pakistan by 2 wickets to take 1-0 lead in series
Singham Again’s sole aim is to entertain, it’s not Hindutva propaganda
Delhi pollution: 'Why firecracker ban was not implemented during Diwali,' SC asks police, govt
IPL 2025 mega auction likely to be held in Riyadh on these dates
Big update on Reliance Jio IPO as Mukesh Ambani eyes THIS date
EC reschedules UP, Punjab, Kerala bypolls from Nov 13 to...
Coldplay's Chris Martin falls through stage trap door while performing live in Australia
Meet man, who is rising star in Tata Group after Ratan Tata's death, now tasked with...
'Nice handwriting': Internet reacts to Elon Musk's physics homework from his college days
AIIMS INI CET 2025 admit card releasing today at aiimsexams.ac.in; when and how to download
Sustainability Meets Innovation via uPVC: Industry expert shares experience
Promoting innovation in engineering education
AP TET 2024 exam result declared at aptet.apcfss.in; steps to check
AI-Powered Development: Insights from industry leaders on transforming software engineering
Another BIG move by BSNL, now set to provide tough competition to Jio, Airtel, Vi by...
Bigg Boss 18: Vivian D'Sena accuses Chahat Pandey of pooping on floor, latter loses her cool
Uttarakhand Bus Accident: 36 dead after bus falls into gorge in Almora; rescue operations underway
One of India's best wicketkeepers set to retire after this season, won't play IPL too, he is...
Research shows awe-inspiring details about Black Holes, they can...
US Presidential Election 2024: Harris vs Trump goes down to the wire, say polls
AP TET 2024 exam result to be declared today on aptet.apcfss.in, when and how to check
Shampoo, tea, biscuits, oil to get costlier soon? FMCG firms caution price hike as...
Swiggy fined Rs 35000 for duping Hyderabad customer by doing THIS
Delhi pollution: Air quality in Delhi-NCR further deteriorates, AQI hits 'severe' level
Indian mission condemns attack on Hindu devotees at Canada temple by ‘anti-India’ elements
'Upar se leke neeche tak...': Bigg Boss 18's Kashish Kapoor, Eisha Singh get into ugly spat
Man grows 500 kg pumpkin, uses it as boat to sail 70 km, SEE PIC
Devotees at Banke Bihari Temple drink AC water believing it to be 'Charan Amrit'; WATCH viral video
Bank Holidays in November: Banks to remain closed for four days in THESE states, full list here
Bhool Bhulaiyaa 3: Kartik Aaryan's mother struggles to get tickets, hilarious video goes viral
Mumbai Police arrest Maharashtra woman for hoax death threat to UP CM Yogi Adityanath
Kriti Sanon avoids posing with rumoured boyfriend Kabir Bahia at Mumbai airport, video goes viral
This is world's most expensive house, twice price of Mukesh Ambani's Antilia, it is located in...
SC to hear today Delhi govt's plea against vesting LG with power to appoint...
Viral video: Girl’s sizzling dance to ‘Taareefan’ song earns praise from netizens, watch
Watch: Elderly couple's heartwarming dance at Mohit Chauhan's Patna concert goes viral
This is India’s most expensive wedding card, made from real gold and silver, it costs Rs…
Viral video: Men’s mid-air stunt, twerk on Mumbai local train leaves netizens in splits, watch
Kartik Aaryan reveals details about his new 'girlfriend': 'Her name is...'
Delhi pollution: Air quality worsens in capital, AQI worst in India at...
Singham Again movie review: Ajay Devgn, Akshay Kumar, Ranveer Singh's high octane actioner
Pune: 35-year-old man killed by speeding car while bursting firecrackers on Diwali, video surfaces
Shah Rukh Khan makes BIG revelation on his birthday, says he has quit...
‘Against the principles of…’: Vijay-led TVK passes resolution against One Nation One Election
Watch: Two Delhi traffic police personnel dragged for 20 metres, case filed
Delhi-NCR pollution: Targeted measures enforced under GRAP for 16 days from...
AUS vs PAK Live Streaming: When and where to watch Australia vs Pakistan 1st ODI in India?
Viral video: Man casually lies on Delhi metro floor, leaves netizens divided